Johnson & Johnson

Johnson & Johnson shares are getting a fresh catalyst after the FDA cleared its Ottava surgical robot for use. The De Novo authorization opens a $6 billion market that Intuitive Surgical has dominated for years. J&J now has a direct competitor in robotic-assisted surgery, a segment where it has tried and failed before. The stock sits near the middle of its 52-week range, with a P/E just under 30. Momentum is the strongest piece of the Alpha Score at 82.3, while value lags at 40.2. Quality scores a solid 75.5, reflecting net margins above 21%. Revenue grew 8.1% last year, and EPS jumped 320% — though that number is skewed by a low base. The Ottava approval gives the healthcare giant a new growth leg at a time when its pharmaceutical pipeline faces patent cliffs. The next question is how fast hospitals adopt the system against Intuitive's installed base. J&J reports next quarter in mid-April.

Johnson & Johnson shares sit near the top of a wide 52-week band, with an Alpha Score of 63.6 anchored by momentum at 82.3. That momentum reflects a 320.3% EPS spike — a figure that looks dramatic but owes more to base effects and prior-year write-offs than to organic acceleration. Revenue rose 8.1%, steady for healthcare but not breakout territory. Value scores lag at 40.2, unsurprising given the 29.98 P/E. The quality score of 75.5 suggests the margin story holds up: net margin sits at 21.5%, healthy for a firm carrying legacy consumer liabilities. Sentiment sits at 50, neutral. Friday's close marks little net change from the prior week. The next catalyst? Trial readouts in the medtech pipeline could shift sentiment if they hit or miss. For now, the stock is priced for the earnings jump to sustain, not expand.

Johnson & Johnson shares are trading near the bottom of their 52-week range, a zone that has historically drawn value buyers. The stock carries a P/E of 29.4 on earnings of $8.65 per share, a multiple that looks stretched against the 3.9% decline in EPS over the past year. Revenue growth of 7.9% provides some cover, but the earnings contraction is the metric that matters for the valuation debate. The Alpha Score of 59.4 reflects a split picture. Momentum scores 80.7, suggesting the recent slide may be overdone in the eyes of trend followers. Value scores 39.8, confirming the market sees limited bargain appeal at current levels. Quality and sentiment sit in the middle, at 60.9 and 50 respectively. What to watch next: the company's next quarterly report will need to show EPS growth turning positive to justify the current multiple. If earnings continue to shrink, the stock could test the $155 area, the low end of its 52-week range.

Johnson & Johnson trades at 29.4 times earnings with revenue up 7.9% from a year ago. EPS fell 3.9% in the same period, a gap that keeps the net margin at a still-healthy 21.8%. The Alpha Score of 59.9 is pulled up by momentum (82.4) and dragged by value (39.8), reflecting a stock that has run near its 52-week high of $269.43. Lynk Pharmaceuticals finished enrollment in a Phase III trial for a JAK1 inhibitor, an oral drug for active ankylosing spondylitis. That puts a competitor in the same mechanism class as JNJ's Xeljanz, though the readout is still months away. The quality score of 60.9 suggests the business is sound but not exceptional. Next week's catalyst: the quarterly earnings calendar.

Johnson & Johnson shares edged lower Friday, settling near $245 after Ken Griffin's Citadel added 146% to its position in Q1. The 1.93 million share stake from a famously risk-conscious hedge fund manager caught the Street's attention, but the stock's 52-week range tells a different story — down 9% from the $269 high and still 58% above the $155 low. The numbers underneath are mixed. Revenue grew 7.9% year over year, and net margins sit at a healthy 21.8%. But EPS fell 3.9% over the same period, and the 29.4 P/E is rich for a company with single-digit top-line growth. The Alpha Score of 61.4 reflects that tension: momentum scores 87.3, value just 39.8. Next week's focus is the quarterly ex-dividend date. The 2% yield is safe but not a growth story. Watch whether the Griffin endorsement draws more institutional buyers into a name that's been range-bound since February.